Jiangsu wuzhong(SH:600200) Zhong Guo Zheng Quan Bao·2025-08-27 15:16Core Viewpoint - *ST Suwu has issued multiple warnings regarding significant trading risks and potential forced delisting due to abnormal stock price fluctuations and regulatory issues [1][3][7]. Group 1: Trading Risks - On August 27, *ST Suwu announced that its stock price had deviated significantly, with a cumulative increase of over 12% in two consecutive trading days, indicating abnormal trading activity [4]. - The stock experienced a substantial increase over five consecutive trading days, with a trading turnover rate of 20.93% on August 27, suggesting a "hot potato" trading phenomenon [4]. - The company has warned that if further significant trading anomalies occur, it will apply for a trading suspension to protect the rights of small investors [4]. Group 2: Regulatory Issues - *ST Suwu received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, indicating that the company had inflated its operating income, costs, and profits, leading to false records in annual reports from 2020 to 2023 [7]. - The company is at risk of being subjected to forced delisting due to these violations of the Shanghai Stock Exchange listing rules [7][9]. - As of July 14, *ST Suwu's stock has been under a delisting risk warning, and if the CSRC's final decision confirms the violations, the stock will be terminated from listing [9]. Group 3: Financial and Operational Status - The company conducted a self-examination and found no significant changes in its daily operations or external environment that would impact its stock price, nor any undisclosed major events [6]. - The controlling shareholder's related parties have non-operating fund occupation amounting to 1.693 billion yuan as of the end of 2023 [9]. - The company is currently facing operational challenges due to a contract termination with Regen Biotech Inc., affecting its ability to sell AestheFill products [9].